title: Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes.
abstract: OBJECTIVE
  We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative age-related macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice.
  
  
  METHODS
  Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression.
  
  
  RESULTS
  Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections.
  
  
  CONCLUSIONS
  These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice.
authors.affiliation: The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia. mark.gillies@sydney.edu.au
authors.forename: Mark C
authors.initials: MC
authors.lastname: Gillies
authors.forename: Richard
authors.initials: R
authors.lastname: Walton
authors.forename: Judy M
authors.initials: JM
authors.lastname: Simpson
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Arnold
authors.forename: Robyn H
authors.initials: RH
authors.lastname: Guymer
authors.forename: Ian L
authors.initials: IL
authors.lastname: McAllister
authors.forename: Alex P
authors.initials: AP
authors.lastname: Hunyor
authors.forename: Rohan W
authors.initials: RW
authors.lastname: Essex
authors.forename: Nigel
authors.initials: N
authors.lastname: Morlet
authors.forename: Daniel
authors.initials: D
authors.lastname: Barthelmes
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D001315:Australia; D000068258:Bevacizumab; D054869:Clinical Audit; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D011446:Prospective Studies; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab
keywords: anti-VEGF; neovascular age-related macular degeneration; observational study